Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure

Circulation Journal

Volumn 78, Issue 9, 2014, Pages 2240-2249

  Imamura, Teruhiko ^a   Fujino, Takeo ^a   Inaba, Toshiro ^a   Maki, Hisataka ^a   Hatano, Masaru ^a   Yao, Atsushi ^a   Komuro, Issei ^a   Kinugawa, Koichiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chronic kidney disease; Congestive heart failure; Diabetes insipidus; Diuretics

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; AQUAPORIN 2; ARGIPRESSIN; ASPARTATE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILIRUBIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HEMOGLOBIN; POTASSIUM; SODIUM; TOLVAPTAN; TRICHLORMETHIAZIDE; AQP2 PROTEIN, HUMAN; BENZAZEPINE DERIVATIVE; BIOLOGICAL MARKER; VASOPRESSIN RECEPTOR ANTAGONIST;

ACUTE HEART FAILURE; ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; OBSERVATIONAL STUDY; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; URINALYSIS; URINE VOLUME; AGED; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HEART FAILURE; METABOLISM; SURVIVAL RATE; URINE;

ADULT; AGED; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; AQUAPORIN 2; ARGININE VASOPRESSIN; BENZAZEPINES; BIOLOGICAL MARKERS; DISEASE-FREE SURVIVAL; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 84906818882     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0244     Document Type: Article

References (35)

1. Uretsky BF, Verbalis JG, Generalovich T, Valdes A, Reddy PS. Plasma vasopressin response to osmotic and hemodynamic stimuli in heart failure. Am J Physiol 1985; 248(3 Pt 2): H396-H402.
2. Lanfear DE, Sabbah HN, Goldsmith SR, Greene SJ, Ambrosy AP, Fought AJ, et al. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: Insights from the EVEREST trial. Circ Heart Fail 2013; 6: 47-52.
3. Goldsmith SR. Vasopressin as vasopressor. Am J Med 1987; 82: 1213-1219.
4. Nielsen S, Kwon TH, Christensen BM, Promeneur D, Frokiaer J, Marples D. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999; 10: 647-663.
5. Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, et al. Tolvaptan can improve clinical course in responders. Int Heart J 2013; 54: 377-381.
6. Kinugawa K, Imamura T, Komuro I. Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients. Clin Pharmacol Ther 2013; 94: 449-451.
7. Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006; 290: F273-F278.
8. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112.
9. Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: An international, multicenter, randomized, placebo- controlled trial. J Am Coll Cardiol 2008; 52: 1540-1545.
10. Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21: 705-712.
11. Matsuzaki M, Hori M, Izumi T, Fukunami M. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: A phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 2011; 25 (Suppl 1): S33-S45.
12. Kinugawa K, Sato N, Inomata T, Shimakawa T, Iwatake N, Mizuguchi K. Efficacy and safety of tolvaptan in heart failure patients with volume overload. Circ J 2014; 78: 844-852.
13. Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients: Association between non-responders and chronic kidney disease. Circ J 2013; 77: 397-404.
14. Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, et al. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients. Circ J 2013; 77: 1208-1213.
15. Rai T, Sekine K, Kanno K, Hata K, Miura M, Mizushima A, et al. Urinary excretion of aquaporin-2 water channel protein in human and rat. J Am Soc Nephrol 1997; 8: 1357-1362.
16. Kinugawa K. How to treat stage D heart failure? When to implant left ventricular assist devices in the era of continuous flow pumps? Circ J 2011; 75: 2038-2045.
17. Umenishi F, Summer SN, Cadnapaphornchai M, Schrier RW. Comparison of three methods to quantify urinary aquaporin-2 protein. Kidney Int 2002; 62: 2288-2293.
18. Sasaki S, Ohmoto Y, Mori T, Iwata F, Muraguchi M. Daily variance of urinary excretion of AQP2 determined by sandwich ELISA method. Clin Exp Nephrol 2012; 16: 406-410.
19. Garin O, Ferrer M, Pont A, Rue M, Kotzeva A, Wiklund I, et al. Disease-specific health-related quality of life questionnaires for heart failure: A systematic review with meta-analyses. Qual Life Res 2009; 18: 71-85.
20. Kato N, Kinugawa K, Seki S, Shiga T, Hatano M, Yao A, et al. Quality of life as an independent predictor for cardiac events and death in patients with heart failure. Circ J 2011; 75: 1661-1669.
21. Joffe MM, Rosenbaum PR. Invited commentary: Propensity scores. Am J Epidemiol 1999; 150: 327-333.
22. Fushimi K, Uchida S, Hara Y, Hirata Y, Marumo F, Sasaki S. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 1993; 361: 549-552.
23. Sasaki S, Fushimi K, Saito H, Saito F, Uchida S, Ishibashi K, et al. Cloning, characterization, and chromosomal mapping of human aquaporin of collecting duct. J Clin Invest 1994; 93: 1250-1256. Erratum in: J Clin Invest 1994; 94: following 216.
24. Radin MJ, Yu MJ, Stoedkilde L, Miller RL, Hoffert JD, Frokiaer J, et al. Aquaporin-2 regulation in health and disease. Vet Clin Pathol 2012; 41: 455-470.
25. Elliot S, Goldsmith P, Knepper M, Haughey M, Olson B. Urinary excretion of aquaporin-2 in humans: A potential marker of collecting duct responsiveness to vasopressin. J Am Soc Nephrol 1996; 7: 403-409.
26. Kanno K, Sasaki S, Hirata Y, Ishikawa S, Fushimi K, Nakanishi S, et al. Urinary excretion of aquaporin-2 in patients with diabetes insipidus. N Engl J Med 1995; 332: 1540-1545.
27. Ishikawa SE, Saito T, Fukagawa A, Higashiyama M, Nakamura T, Kusaka I, et al. Close association of urinary excretion of aquaporin-2 with appropriate and inappropriate arginine vasopressin-dependent antidiuresis in hyponatremia in elderly subjects. J Clin Endocrinol Metab 2001; 86: 1665-1671.
28. Funayama H, Nakamura T, Saito T, Yoshimura A, Saito M, Kawakami M, et al. Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure. Kidney Int 2004; 66: 1387-1392.
29. Kleeman CR, Adams DA, Maxwell MH. An evaluation of maximal water diuresis in chronic renal disease. I. Normal solute intake. J Lab Clin Med 1961; 58: 169-184.
30. Teitelbaum I, Mcguinness S. Vasopressin resistance in chronic renal failure: Evidence for the role of decreased V-2 receptor messenger- RNA. J Clin Invest 1995; 96: 378-385.
31. Bedford JJ, Leader JP, Walker RJ. Aquaporin expression in normal human kidney and in renal disease. J Am Soc Nephrol 2003; 14: 2581-2587.
32. Martin PY, Abraham WT, Lieming X, Olson BR, Oren RM, Ohara M, et al. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol 1999; 10: 2165-2170.
33. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 2007; 297: 1319-1331.
34. Hauptman PJ, Burnett J, Gheorghiade M, Grinfeld L, Konstam MA, Kostic D, et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail 2013; 19: 390-397.
35. Gheorghiade M, Gattis WA, O’Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA 2004; 291: 1963-1971.